H. Miles Prince

Peter MacCallum Cancer Institute
Country flagAustralia

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (26)

Year:

2026

Year:

2026

Year:

2026

Background/Objectives Cutaneous manifestations of Waldenstrom's macroglobulinaemia (WM), a rare B‐cell lymphoproliferative disorder, present a diagnostic challenge. The intent of this article is to raise awareness to clinicians of a potentially overlooked condition, particularly in the context of patients with a monoclonal IgM paraproteinaemia, but also to describe the diagnostic complexity of the disease from a clinicopathological perspective. Methods We describe the clinical presentation and histopathological findings of two patients with cutaneous involvement of WM. Results Cutaneous presentations included erythematous and salmon pink plaques, which were either tender or non‐tender. Histopathology analysis in both cases demonstrated direct lymphocytic infiltration by malignant lymphocytes of WM, with case 1 demonstrating aberrant CD10 expression. Conclusion The broad cutaneous signs of WM are sparsely described in the literature, and these can even precede formal diagnosis. Ongoing clinical suspicion is warranted from both a clinical and histopathological perspective where patients present with a monoclonal IgM paraproteinemia.

Year:

2026

Advanced mycosis fungoides (MF) and Sézary syndrome (SS) have a poor overall survival (OS) of <5 years. Studies have found the current staging (IA-IVB) is inadequate for risk stratification. The PROCLIPI (Prospective Cutaneous Lymphoma International Prognostic Index) study was launched in 2015 at 46 international expert MF/SS centers, prospectively collecting predefined data sets in patients with newly diagnosed MF/SS, to determine a cutaneous lymphoma IPI (CLIPI). Five hundred fifty-two patients with advanced stage MF/SS were recruited. The 5-year OS was 50.0% for stage IIB, 64.8% for stage IIIA, 43.9% for stage IIIB, 50.8% for stage IVA1, 25.9% for stage IVA2, and 36.9% for stage IVB. Factors at diagnosis associated with a significantly worse survival were N3 status (P < .001), age >60 years (P < .001), raised serum lactate dehydrogenase (P = .005), and large-cell transformation in skin (P = .006). Modeling these 4 independent risk factors into a CLIPI found that there was a worse OS in high- vs low-risk (P < .001), high- vs intermediate-risk (P = .002) and intermediate- vs low-risk (P = .010) groups. Five-year OS was 63.3%, 44.7%, and 18.3% in the low-, intermediate-, and high-risk groups, respectively. In this advanced stage cohort there was a low 5-year survival and increasing stage was not associated with worsening survival. The use of CLIPI to stratify patients into risk groups has the potential to improve outcomes and aid optimal treatment selection. This trial was registered at www.ClinicalTrials.gov as #NCT02848274.

Year:

2025

PURPOSE Denileukin diftitox (DD)-cxdl is a fusion protein comprising diphtheria toxin fragments A and B and human interleukin-2. This phase III, multicenter, open-label, single-arm registrational trial evaluated the efficacy and safety of DD-cxdl in patients with relapsed/refractory (R/R) cutaneous T-cell lymphoma (CTCL). PATIENTS AND METHODS In the main study, which followed a dose-finding lead-in, DD-cxdl was administered intravenously daily (5 days; 9 µg/kg/d once daily) every 21 days for up to eight cycles. Patients in the primary efficacy analysis set (PEAS) were required to have stage IA-IIIB CTCL (mycosis fungoides and/or Sézary syndrome) and at least ≥one previous systemic therapy. The primary efficacy end point was objective response rate (ORR) using the Global Response Score. Secondary end points were duration of response (DOR), time to response (TTR), skin tumor burden, and safety and tolerability. RESULTS The PEAS included 69 patients (median age, 64.0 years). The ORR was 36.2% (95% CI, 25.0 to 48.7), including 8.7% with complete response. The median DOR was 8.9 months (95% CI, 5.0 to not estimable), and the median (Q1-Q3) TTR was 1.4 (0.7-2.1) months. A total of 84.4% of patients showed decreased skin tumor burden, with 48.4% showing a ≥50% decrease. Treatment-emergent adverse events (TEAEs) of special interest, most of which were grade 1 or 2, included infusion reaction (73.9%), hypersensitivity (68.1%), hepatotoxicity (36.2%), and capillary leak syndrome (20.3% [grade ≥3, 5.8%]). Other common TEAEs were nausea (43.5%) and fatigue (31.9%). CONCLUSION Efficacy and safety results show that DD-cxdl would potentially fulfill a serious, unmet medical need for patients with R/R CTCL.

Year:

2025

Large‐cell transformation of mycosis fungoides (LCTMF) is rare, histologically distinct, with an aggressive clinical course; yet is not recognised as an independent entity in classification systems nor in staging systems for mycosis fungoides and Sézary syndrome (MF/SS). Herein, the patterns of care and survival outcomes for patients with LCTMF are described, with prognosis compared to published data of non‐transformed MF/SS. Eligibility required clinicopathological diagnosis of LCTMF (1/1/1990–31/10/2021), managed at Peter MacCallum Cancer Centre. Eighty‐three patients were eligible. Median follow‐up was 8.0 years. At the time of LCTMF, 36% had early‐stage MF (IA‐IIA), 76% had cutaneous‐only LCTMF. The most common first‐line treatments were localised radiotherapy (48%) and multiagent chemotherapy (23%). Median overall survival (OS) from LCTMF diagnosis was 3.5 years (95% [confidence interval] CI: 2.2–8.2). Three prognostic groups of LCTMF were identified: unifocal cutaneous only, multifocal cutaneous only and extracutaneous (median OS: 4.6, 2.5 and 1.1 years, respectively; p = 0.005). Unfavourable prognostic factors were advanced age and extracutaneous LCTMF. In conclusion, treatment pathways for patients with LCTMF were varied, and prognosis was poor, despite >1/3 having early‐stage MF. However, differences in prognosis were suggested, with unifocal cutaneous LCTMF associated with greater OS. Given prognostic differences from MF/SS, consideration to include LCTMF in staging systems is warranted.

Year:

2025

Background Cutaneous T-cell lymphomas (CTCLs) are rare with distinct diagnostic challenges. Equitable access to cancer care is a recognized priority, internationally. To date, the geospatial distribution of CTCL has not been definitively studied. Understanding the incidence and geographical distribution of patients with CTCL are critical first steps towards the ultimate goal of equity of care. Geospatial analyses also allow the opportunity to explore environmental causative factors: for CTCL, the contribution of solar ultraviolet (UV) radiation on causation remains unclear. Objectives We investigate geospatial patterns of CTCL incidence across Australia, compare with all rare cancers, and consider solar UV exposure on causality and diagnosis rates. Methods All CTCL diagnoses (1 January 2000 to 31 December 2019) were obtained from the nationwide dataset. Areas of residence were collected according to nationally approved definitions. Bayesian spatial incidence models were applied. Geospatial distributions were visually analysed. Results The CTCL age-standardised incidence rate was 7.7 (95% confidence interval 7.4–7.9) per million people per year in Australia. Diagnostic disparity was seen between Australian states/territories, with lower diagnosis rates in rural/remote and socioeconomically disadvantaged areas. Incidence exceeded the national average within more densely populated capital cities. Visual comparisons of the geospatial distribution of CTCL revealed marked discordances with the geospatial patterns of all rare cancers and solar UV in Australia. Conclusions Geographical heterogeneity in CTCL exists across Australia. Incidence reflects population density. Geospatial patterns of CTCL differ substantially from all rare cancers, with implications for the unique diagnostic challenges and unmet needs of this patient population. The distribution of CTCL across Australia does not support a causative link with UV exposure. Further global evaluation of geospatial patterns is warranted.

Year:

2025

Year:

2025

The phase 2, multicohort, ongoing ELM-2 study evaluates odronextamab, a CD20×CD3 bispecific antibody, in patients with relapsed/refractory (R/R) B cell non-Hodgkin lymphoma after ≥2 lines of therapy. Here primary analysis of the diffuse large B cell lymphoma (DLBCL) cohort is reported. Patients received intravenous odronextamab in 21-day cycles until progression or unacceptable toxicity, with cycle 1 step-up dosing to mitigate cytokine release syndrome (CRS) risk. The primary endpoint was objective response rate (ORR). Secondary endpoints included complete response (CR) rate, duration of response, progression-free survival (PFS) and overall survival. A total of 127 patients were enrolled. At the 29.9-month efficacy follow-up, the ORR was 52.0% and CR rate was 31.5%. Median durations of response and CR were 10.2 and 17.9 months, respectively. Undetectable minimal residual disease at cycle 4 day 15 was associated with PFS benefit. With a step-up of 0.7 to 4 to 20 mg ( n = 60), CRS was the most common treatment-emergent adverse event (53.3% (grade ≥3, 1.7%)). No immune effector cell-associated neurotoxicity syndrome was reported. Infections were reported in 82/127 (64.6%) patients (grade ≥3, 38.6%; coronavirus disease 2019, 18.1% (grade ≥3, 12.6%)). In conclusion, odronextamab showed encouraging efficacy in heavily pretreated R/R DLBCL and generally manageable safety with supportive care. Clinical trial registration: NCT03888105 .

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Collaborators (24)

Felicity Evison

University Hospitals Birmingham NHS Foundation Trust

UNITED KINGDOM
View details

Chan Yoon Cheah

University of Western Australia

AUSTRALIA
View details

Oleg Akilov

Associate Professor

University of Pittsburgh School of Medicine

UNITED STATES
View details

Shane Gangatharan

University of Western Australia

AUSTRALIA
View details

Robert Weinkove

Clinical Director

Malaghan Institute of Medical Research

NEW ZEALAND
View details

Emmanuella Guenova

Chair

University of Zurich

SWITZERLAND
View details

Julia J Scarisbrick

-

UNITED KINGDOM
View details

Belinda A. Campbell

department of medicine university of melbourne melbourne victoria australia

AUSTRALIA
View details

Tae Min Kim

Seoul National University Hospital

SOUTH KOREA
View details

Judith Trotman

Head of Department

Concord Repatriation General Hospital

AUSTRALIA
View details

Steven Lane

LAB HEAD

QIMR Berghofer Medical Research Institute

AUSTRALIA
View details

Craig Underhill

-

AUSTRALIA
View details

Michelle Yong

University of Melbourne

AUSTRALIA
View details

Stephen Opat

Monash Health

AUSTRALIA
View details

Martine Bagot

Prof and Head

Université Paris-Saclay

FRANCE
View details

Francine Foss

Yale University

UNITED STATES
View details

Gandhi Damaj

Professor, M.D. Head of departement

University Hospital

FRANCE
View details

Jan Walewski

Professor of Medicine, Consultant in Medical Oncology

Narodowy Instytut Onkologii im Marii Skłodowskiej-Curie Państwowy Instytut Badawczy w Warszawie

POLAND
View details

Thomas Jandl

Assistant Professor

Stony Brook University Hospital

UNITED STATES
View details

JIN SEOK KIM

Associate Professor

Severance Hospital

SOUTH KOREA
View details

Claire M. Vajdic

University of New South Wales

AUSTRALIA
View details

John F. Seymour

Peter MacCallum Cancer Institute

AUSTRALIA
View details

Youn H. Kim

Professor/Director

Stanford University

UNITED STATES
View details

Graham Giles

Head of Research

-

AUSTRALIA
View details